Advertisement

Advertisement
Breast Cancer
Immunotherapy

Tucatinib Combination Extends Survival in HER2-Positive Metastatic Breast Cancer, Including Patients With Brain Metastases

For patients with progressing HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and ado-trastuzumab emtansine...

Issues in Oncology

Practicing Wellness to Reduce Burnout

Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard-of-care...

Issues in Oncology
Breast Cancer
Survivorship
Prostate Cancer

Elevations in Cancer Incidence Among Responders to the WTC Site After the September 11 Attacks

We’ll start off this week on The ASCO Post Podcast by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes...

 

 

 


Advertisement
Hematologic Malignancies

Preliminary Data on Multiantigen-Targeted CAR NK-Cell Therapy for B-Cell Malignancies

A novel off-the-shelf chimeric antigen receptor natural killer cell (CAR-NK) product called FT596 may prove to be an active therapy for B-cell malignancies...

Breast Cancer

Breast Cancer Chemoprevention Effect Maintained Long After Stopping Anastrozole Therapy

For postmenopausal women at high risk for developing breast cancer—largely based on family history—anastrozole taken for 5 years maintained...

Advertisement




More Top Stories

Breast Cancer

Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Retrospective Analysis of PD-L1 Immunohistochemistry Assays

Skin Cancer

Molecular Characteristics of Leptomeningeal Melanoma Metastases

Patients with advanced melanoma who develop metastases in the leptomeninges usually have a poor prognosis—most patients only survive for 8 to 10 weeks after diagnosis. One reason for this poor prognosis is that very little is known about the molecular development of leptomeningeal melanoma...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Tari A. King, MD, on Molecular Differences Between Primary and Metastatic Breast Tumors

Hepatobiliary Cancer

Treatment Resistance and Novel Therapies in FGFR-Mutated Cholangiocarcinoma

A new study has shown how resistance to fibroblast growth factor receptor (FGFR) inhibitor treatment develops in patients with cholangiocarcinoma and suggests that adding another therapy at the time of disease progression might resensitize tumor cells to initial therapy. These findings were...

Leukemia

Conditioning Intensity for Allogeneic Transplantation in Patients With AML

In a study reported in the Journal of Clinical Oncology, Hourigan et al found that reduced-intensity conditioning for allogeneic hematopoietic cell transplantation was associated with poorer outcomes vs myeloablative conditioning in patients with acute myeloid leukemia (AML) who had genomic...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Multiple Myeloma

Mark Bustoros, MD, on Ixazomib/Lenalidomide/Dexamethasone for High-Risk Smoldering Multiple Myeloma

Hepatobiliary Cancer
Colorectal Cancer

2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC

Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard-of-care treatments in patients with unresectable hepatocellular carcinoma and BRAF V600E­–mutant metastatic colorectal cancer. The results, from...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...